Chief Executive Officer, Quotient Sciences Mark joined Quotient as Chief Executive Officer in 2005 and has over 25 years’ experience in the pharmaceutical and biotech industries. He has worked in a range of organizations, including large multinational pharmaceutical companies through to private venture funded biotechnology companies. Following his Ph.D. (biochemistry, University of Edinburgh) and post-doctoral research (biochemistry, Biozentrum, Basel), Mark began his pharmaceutical R&D career at Novartis (then Sandoz) in Switzerland and then AstraZeneca in the U.K. During this time, he was responsible for discovery projects across a number of therapeutic areas. Mark then joined Incyte Pharmaceuticals, a Californian biotechnology company, where he was responsible for a business unit focused on the application of genomic technologies to preclinical development. He returned to the U.K. with Incyte Pharmaceuticals to head up European Business Operations and was responsible for leading that organization to record levels of performance. Prior to joining Quotient, Mark was the Chief Business Officer at Oxagen, a U.K. biotech company focused on novel therapeutics for respiratory diseases.